UNSPSC 51322801: Glunicate

This classification denotes an anti-lipidemic agent with the molecular formula C36H28N6O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C62ZH19B0L, chemically known as 2-deoxy-2-nicotinamido-beta-d-glucopyranose 1,3,4,6-tetranicotinate but generally known as glunicate, which bears US NIH Compound Identifier 71243. European Medicines Agency schedules Glunicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07942MIG.

UNSPSC 51322801 Glunicate, a Commodity code, encompasses emergency and acute-care pharmaceutical supplies that state and local governments procure for fire rescue, health and human services, and institutional pharmacy programs. The code captures both individual medication line items and broader pharmaceutical inventory programs sourced through manufacturer-to-wholesaler-to-end-user supply chains. Issuing bodies include city purchasing departments (fire rescue operations), state health and human services commissions, and multistate cooperative purchasing alliances administering contracts across member jurisdictions. Work solicited ranges from sealed-bid procurements for specific emergency medications with firm pricing and expedited delivery to exploratory requests for information and multi-award RFPs establishing standing supply agreements with flexible pricing models and wholesaler distribution.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue — Labetalol, Epinephrine, Adenosine, and Diltiazem — with a $40,000 estimated value, firm pricing including freight, and a one-year contract term with renewal options; the bid deadline was April 8, 2026, and the solicitation carried a 5 percent small local business enterprise discount cap of $10,000. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a direct-to-manufacturer pharmacy initiative outside traditional PBM and wholesaler channels, signaling future formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), effective July 1, 2026, with a two-year initial term and weighted evaluation favoring price competitiveness (75 percent).